Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roche Holding AG Basel American Depositary Shares (OP: RHHBY ) 39.26 +0.45 (+1.16%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,211,621 Open 39.32 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 38.81 Today's Range 39.20 - 39.42 52wk Range 29.20 - 42.43 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer October 30, 2024 From Genentech Via Business Wire Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket October 30, 2024 Via Benzinga Performance YTD +8.01% +8.01% 1 Month +0.49% +0.49% 3 Month -3.56% -3.56% 6 Month +31.61% +31.61% 1 Year +19.48% +19.48% More News Read More Biotech Momentum Trades For The Q4 Rally October 29, 2024 Via Talk Markets Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review October 25, 2024 Via Investor's Business Daily Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition October 23, 2024 Via Benzinga Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales Expectations October 23, 2024 Via Investor's Business Daily Can Roche Challenge Lilly and Novo in the Weight Loss Market? October 22, 2024 Via MarketBeat Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study October 18, 2024 From Genentech Via Business Wire Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up October 18, 2024 Via Investor's Business Daily Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer October 15, 2024 Via Benzinga Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade October 14, 2024 Via Investor's Business Daily Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate October 14, 2024 From Genentech Via Business Wire Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names October 11, 2024 Via Benzinga FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation October 10, 2024 From Genentech Via Business Wire Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday? October 10, 2024 Via Benzinga Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer October 08, 2024 Via Benzinga Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year October 07, 2024 Via Benzinga Exposures Product Safety 2 Artificial Intelligence Stocks That Could Deliver Explosive Gains October 07, 2024 Via The Motley Fool Topics Artificial Intelligence Exposures Artificial Intelligence Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point? October 06, 2024 Via Benzinga Week In Review: Regor Sells Two CDK Inhibitors To Genentech For $850 Million October 05, 2024 Via Talk Markets As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer October 04, 2024 Via Investor's Business Daily 3 Top Stocks That Could Still Rocket Higher in 2024 October 04, 2024 Via The Motley Fool Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential September 30, 2024 Via Benzinga Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis September 26, 2024 From Genentech Via Business Wire Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points September 21, 2024 Via Investor's Business Daily Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
